E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers A > Headlines for AlphaRx Inc. > News item
Published on 7/14/2005 in the Prospect News Biotech Daily.

AlphaRx approves Alpha AP to purchase up to 10% of its stock

By Jennifer Chiou

New York, July 14 - AlphaRx Inc. announced its board has authorized subsidiary Alpha AP Inc. to buy up to 10% of its outstanding common stock, according to an 8-K filing with the Securities and Exchange Commission.

Markham, Ont.-based AlphaRx said Alpha AP will buy the stock open-market purchases.

AlphaRx is a biopharmaceutical company focused on the clinical development of arthritis drug Indaflex.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.